Abstracts tagged "treatment"

Abstract Number: 2481 • 2016 ACR/ARHP Annual Meeting
Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Teresa Jurado¹, Chamaida Plasencia-Rodriguez², Ana Martínez³, Victoria Navarro-Compán⁴, Eva Olariaga-Merida⁵, Diana Peiteado⁶, Alejandro Villalba⁶, Gema Bonilla⁶, Cristina Diego⁷, Alejandro Balsa² and Dora Pascual-Salcedo⁸, ¹Immunology, University Hospital La Paz, Madrid, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁴Rheumatology, University Hospital La Paz, Madrid, Spain, ⁵Immunlogy, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁷Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ⁸Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain
Background/Purpose: The anti-TNF monoclonal antibody Infliximab (Ifx), has proven effective in treating rheumatoid arthritis (RA), although in 40% of cases may fail, mainly due to…
Abstract Number: 2488 • 2016 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis
Stephen Oakley^1,2, Gabor Major^3,4, David Mathers⁵, John van der Kallen⁶, Mark Collins⁷, Marc Toh⁸, Siva Ratnarajah⁸, Theo de Malmanche⁹ and Niloofar Esmaili¹⁰, ¹Rheumatology, Hunter New England Local Health District, New Lambton, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Medicine, University of Newcastle, Newcastle, Australia, ⁴Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ⁵Rheumatology, Hunter New England Local Health District, Georgetown, Australia, ⁶Georgetown Arthritis, Georgetown, Australia, ⁷Private Practice, Broadmeadow, Australia, ⁸Rheumatology, Private Practice, Newcastle, Australia, ⁹Immunology, Hunter New England Local Health District, New Lambton, Australia, ¹⁰Rheumatology, Hunter New England Health, Newcastle, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) risk. The mechanisms of CV disease in RA remain poorly understood. Observational data suggest that…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
Abstract Number: 2581 • 2016 ACR/ARHP Annual Meeting
Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis
Juan Jiao¹, Hai-bo Yin², Xiao-po Tang², Xun Gong² and Quan Jiang¹, ¹Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly…
Abstract Number: 2583 • 2016 ACR/ARHP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Carlos Fernández-Díaz¹, Javier Loricera¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia E. Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez-Muguruza⁴, Bryan Josue Robles Flores⁹, Blanca Hernández-Cruz¹⁰, Ana Urruticoechea¹¹, O. Maiz Alonso¹², Desiree Palma¹³, Luis Arboleya¹⁴, Gema Bonilla¹⁵, Íñigo Hernández-Rodríguez¹⁶, Concepción Delgado¹⁷, Rosa Expósito Molinero¹⁸, Ana Ruibal Escribano¹⁹, Juan Blanco Madrigal²⁰, José Antonio Bernal²¹, Manuel Rodríguez-Gómez²², Paloma Vela Casasempere²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Francisco Ortiz Sanjuan²⁶, Javier Narváez²⁷, Manuel Jose Moreno²⁸, Mireia Lopez-corbeto²⁹, Natalia Mena-Vazquez³⁰, Lucia C. Domínguez-Casas¹, Clara Aguilera-Cros³¹, Victor Mora-Cuesta³², Natalia Palmou-Fontana¹, Miguel Angel Gonzalez-Gay³³, José Luis Hernandez³⁴ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁵Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de Leon, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Can Misses, Ibiza, Spain, ¹²Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹³Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁴Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁵Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ¹⁶Rheumatology, CHUVI Vigo, Vigo, Spain, ¹⁷Rheumatology, Hospital Clinico Universitario Lozano Blesa, zaragoza, Spain, ¹⁸Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ¹⁹Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²⁰Rheumatology, Hospital de Basurto, BIlbao, Spain, ²¹Sección de Reumatología, Hospital General de Alicante, Alicante, Spain, ²²Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²³Rheumatology, Hospital General de Alicante, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology, Hospital La Fe, Valencia, Spain, ²⁷Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ²⁸Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁹Hospital Universitario Vall d'Hebron, Barcelona, Spain, ³⁰Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³³Department of RheumaRheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…
Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 553 • 2016 ACR/ARHP Annual Meeting
Validation of Index of Activity Speed (Timed Up and Go test) for Outcome Measure of Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Toshihisa Kojima¹, Hajime Ishikawa^2,3, Sakae Tanaka⁴, Nobuhiko Haga⁵, Keiichiro Nishida⁶, Masao Yukioka⁷, Jun Hashimoto⁸, Hisaaki Miyahara⁹, Yasuo Niki¹⁰, Tomoatsu Kimura¹¹, Hiromi Oda¹², Shuji Asai¹³, Koji Funahashi¹, Masayo Kojima¹⁴ and Naoki Ishiguro¹⁵, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Orthopedic Surgery, Niigata Rheumatic Center, Shibata, Japan, ³Orthopedic Surgery, Niigata Rheumatic Center, Shinata, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁵Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan, ⁶Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ⁷Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁸Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁹Department of Rheumatology and Orthopaedic Surgery, Kyushu Medical Center, Fukuoka, Japan, ¹⁰Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan, ¹¹Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ¹²Orthopedic Surgery, Saitama Medical Univeristy, Morohongo Moroyama, Japan, ¹³Nagoya University Hospital, Nagoya, Japan, ¹⁴Medical education, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan
Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. It is very…
Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting
The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Sheng-Xiao Zhang¹, Miao Miao², Xiao-Qing Liu², Xiao-Wen Ma², Xiao-Yan Wu² and Xiao-Feng Li¹, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
Abstract Number: 554 • 2016 ACR/ARHP Annual Meeting
Characteristics of Functional Impairment in Patients with Long-Standing Rheumatoid Arthritis Based on Range of Motion of Joints: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Toshihisa Kojima¹, Hajime Ishikawa², Sakae Tanaka³, Nobuhiko Haga⁴, Keiichiro Nishida⁵, Masao Yukioka⁶, Jun Hashimoto⁷, Hisaaki Miyahara⁸, Yasuo Niki⁹, Hiromi Oda¹⁰, Shuji Asai¹¹, Koji Funahashi¹, Masayo Kojima¹² and Naoki Ishiguro¹³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Orthopedic Surgery, Niigata Rheumatic Center, Shibata, Japan, ³Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan, ⁵Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ⁶Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁷Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁸Department of Rheumatology and Orthopaedic Surgery, Kyushu Medical Center, Fukuoka, Japan, ⁹Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan, ¹⁰Orthopedic Surgery, Faculty of Medicine, Saitama Medical Univeristy, Morohongo Moroyama, Japan, ¹¹Nagoya University Hospital, Nagoya, Japan, ¹²Medical education, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan
Background/Purpose: Even now, in clinical practice, most of RA patients have long-standing disease and structural damage in their joints. Reconstructive joint surgery should be needed…
Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen², Timo Yli-Kerttula³, Päivi Ekman⁴, Laura Kuusalo⁵, Laura Pirilä⁶, Markku Mali⁷, Marja Puurtinen-Vilkki⁷, Satu Kortelainen⁷, Johanna Paltta⁶, Kirsi Taimen⁷, Markku J. Kauppi⁸, Kari Laiho⁹, Satu Nyrhinen⁹, Heidi Mäkinen¹⁰, Pia Isomäki¹⁰, Terhi Uotila¹⁰, Kalle Aaltonen¹¹, Hannu Kautiainen¹² and Tuulikki Sokka-Isler¹, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁴Satakunta Central Hospital, Rauma, Finland, ⁵Rheumatology, Turku University Central Hospital, Turku, Finland, ⁶Turku University Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Päijät-Häme Central Hospital, Lahti, Finland, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Helsinki University, Helsinki, Finland, ¹²Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
Abstract Number: 1438 • 2015 ACR/ARHP Annual Meeting
Oral Potassium (K+) Reduces Pain in RA: A Randomized Active Control Study of Diet Based K+ Intervention
Toktam Kainifard¹, Manjit Saluja², Anuradha Venugopalan³, Raju Rane⁴ and Arvind Chopra⁵, ¹Rheumatology, PhD fellow, Pune, India, ²Clinical care, Center for Rheumatic Diseases, Pune, India, ³Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, ⁴Pathology, Pathologist, Pune, India, ⁵Rheumatology, Centre for Rheumatic Diseases, Pune 411001, India
Background/Purpose: National Health and Nutrition Survey III (1988-94,USA) data showed a low K+ body status in RA. Further information is scanty. K+ is critical to…
Abstract Number: 1632 • 2015 ACR/ARHP Annual Meeting
Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Improved means to predict which RA patients will respond to methotrexate monotherapy, the preferred first line therapy in early RA, would allow patients to…
Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Kara Bickham¹, Désirée van der Heijde², Narinder Rawal³, Joachim Sieper⁴, Boyd Scott⁵, Nancy Frontera¹, Sandhya Shah¹, Paul Stryszak¹, Dimitris Papanicolaou¹, Zoran Popmihajlov¹ and Paul Peloso¹, ¹Merck & Co., Inc., Kenilworth, NJ, ²University Hospital, Maastricht, Netherlands, ³Orebro University Hospital, Orebro, Sweden, ⁴Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…
Abstract Number: 1659 • 2015 ACR/ARHP Annual Meeting
Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA
Lisa K. Stamp¹, Jill Drake², John L. O'Donnell³, Christopher Frampton⁴ and Peter T. Chapman⁵, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Immunology, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵Rheumatology, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: It is recommended that all patients receiving MTX also receive at least 5mg/week of folic acid in an effort to reduce occurrence of MTX…
Abstract Number: 1660 • 2015 ACR/ARHP Annual Meeting
Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy
M. Victoria Hernández¹, Jose Inciarte-Mundo², Sonia Cabrera-Villalba³, Virginia Ruiz-Esquide⁴, Julio Ramirez², Andrea Cuervo⁴, Juan D. Cañete^4,5 and Raimon Sanmarti², ¹Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ²Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ⁴Arthritis Unit. Rheumatology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clinic, Barcelona, Arthritis Unit, Rheumatology Department, Barcelona, Spain
Background/Purpose: Dose reduction of biological therapy in patients with chronic arthritis (CA) with good clinical response is a common pattern in clinical practice. However, most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].